Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
RPRX 7.81
If IBB cooperates this wants to run for AdCom (November 3rd)
RPRX 7.55 AdCom Nov 3rd
I believe it is a great entry price
RPRX, they had abt 38 million at the end of March and burned 8 million in last Q, so I guess it should def hold them post November (1 year worth).
RPRX, I did a quick DD on this a couple of months ago but if Im correct their cash on hand isnt too great so I was waiting for them to raise some.
I believe its a good one for November
MACK in at 9.87
RPRX AdCom in November
Nice reverse today
PTN 0.945
The Short sellers are leaving and Im guessing thats a good sign...
http://www.dakotafinancialnews.com/palatin-technologies-sees-large-drop-in-short-interest-ptn/251596/
MSTX - From a scientific standpoint I am not sure about the possibility of success for their poloxamerr product to treat acute limb ischemia.
Ischemia in sickle cell disease is caused due to blockage of blood vessels by sickle or deformed red blood cells. If there is no blood/oxygen going to those tissues I do not understand how coating or putting a Band-Aid in their cell membranes prevents or treats ischemic damage. The best way to treat is to restore blood flow as soon as possible, as is proven in acute myocardial infarction.
As for the stock, I do not know what it will or can do :)
AMRN- 5.27 what are the chances of a quick bear raid before 4PM? I have seen too many of them by now and will be ready for it.
AMRN i think its a good entry point.. Most of the panel is endocrinologists and not cardiologists so I dont think they will want outcome data from the REDUCE IT trial
AMRN 6.20 down from 7.30 yesterday AM
-should bounce back up for the ADCOM meeting
-i believe it will get the thumbs up because it has a SPA and they reached statistical significance in the study for lowering TG in the 250-500 group with basically no significant adverse effect.. Why wouldnt they approve it? AF says that maybe because it opens up Vascepa to a large number of pts and there is no data pn clinical significance of lowering TG... The study was designed to lower TG and not to show clinical benefit for CV death.. That is what the REDUCE IT trial is for
ETRM added at 1.13
Protect your profits $heffites.. Congrats on the wins.
With the possible shutdown fiasco and debt ceiling coming up im out for now.. Im just daytrading at this point looking for bounce plays and also put some in a short ETF (VXX)
ETRM...Great pick $heff. Been watching it for 2-3 months now and I got in yesterday and added today..
ETRM 1.15 a good one to get into IMO for a play
AMRN- I am not sure what the short numbers are, but I believe they covered in the 5's after the company sold shares as per Adam Feuerstein's article couple of months ago.
I had AMRN earlier but at this point I am not eager to get in. It is sporting over a Billion dollar Market Cap with sales in the <10 million per quarter (though that was the first quarter and prescriptions are still rising). Plus with the patent issue still hanging over the risk reward ratio is not too enticing now.
It is however a momentum stock with a great following, so that might do wonders but be careful and watch it closely.
VELT the drop was as if the company declared bankruptcy.. It is overdone given that it is a company with a product being used by companies such as Toyota, Coca Cola, etc and brings in abt 25 million in revenue per quarter in a hot field.. If a couple of things happen for the company it could bounce up hard IMO
It apparently had a lot of revenue in Greece and Cyprus that is beinv written off as it is being unpaid due to the bad e onomy there... They have abt 8 mill in revenue per Q in US
I believe so.. The company has revenue in the 25 million range per quarter and is in the mobile ad business.. Look at Facebook and qhere it started to generate the most money---from mobile advertising..
If a couple of things happen for them
It can bounce and bounce hard..
Due for a bounce up.. Even companies that declared bankruptcy did not go straight down like this.. This company has millions in revenues but just has to focus its business better no?
Nasdaq trading glitch. I think that panicked some of the VELT stockholders
VELT in at 0.39
AMRN 5.88 Consolidatimg well in this range nefore the next leg up
You guys are awesome for
the work that you do..the board feels like family.. Thank you Sheff
PBMD 2.39 reentered here (had a small loss bought 2.67 and sold at 2.60) for October data
Sorry not ETRM but VICL
ETRM 1.52 Sold at 1.62 because there was a 400k block at 1.64 that couldnt be broken.. Had a tight stop becauuse its a volatile one.. Will look to reenter lower
VICL 1.64 Entered at 1.61 for a rebound
It dropped from high 3's on failed data for its Melanoma drug
Here is an excerpt from TheStreet:
From a technical perspective, VICL bounced higher here right above its recent 52-week low at $1.37 with monster upside volume. This stock recently gapped down big from $3.75 to $1.37 with huge downside volume. That move has now pushed shares of VICL into extremely oversold territory, since its current relative strength index reading is 21.80. Oversold can always get more oversold, but it's also an area where a stock can experience a powerful bounce higher from.
Traders should now look for long-biased trades in VICL as long as it's trending above its 52-week low at $1.37 and then once it sustains a move or close above Tuesday's high of $1.63 with volume that hits near or above 1.53 million shares. If we get that move soon, then VICL will set up to re-fill some of its previous gap down zone that started at $3.75. Some possible upside targets if VICL gets into that gap with volume are $2.25 to $2.50.
AMRN 5.70 sold from 5.52 entry for a nice profit
AMRN 5.65 New HOD on excellent volume
AMRN 5.54 HOD Great entry IMO
AMRN 5.46 Has nice targets from yesterday
citigroup lowered target to $11 (13)
Jefferies lowered target to $20 (24)
AMRN 5.49 Entered here for AdCOM play in October
There is high interest in the stock and it has held this level despite not great earnings/sales but with the upcoming catalyst the shorts should cover because they have won enough this year and longs will bet on success..
Awesome news.. May they continue their full recovery to health and peace..
APPY re-entered at 1.48
PBMD added at 2.6 (average 2.67). Will do well in my opinion over the next 2 months
CYTK Sold this AM between 10.45-10.62
Swung from a loss of 500 yesterday to a gain of 200 on it
CYTK- I think you are correct even though I am holding shares from 10.3. Watching it trade on L2, as soon as it goes up a bit, it gets knocked back doown..
OT TSLA $157 Anyone thinking of shorting this?
Great Trade and Great entry in my opinion..